Patents by Inventor Laura E. Strong

Laura E. Strong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10835609
    Abstract: In some aspects, methacrylate co-polymers crosslinked with an enzymatically cleavable peptide linker are provided and may be used for the oral delivery of a therapeutic. The peptide linker may be cleavable by an enzyme in the small intestine and may allow for the delivery of a therapeutic protein or nucleic acid to the small intestine. Also provided are methods of using the polymers for the treatment of a disease.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: November 17, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jennifer M. Knipe, Laura E. Strong, Nicholas A. Peppas
  • Publication number: 20180256724
    Abstract: In some aspects, methacrylate co-polymers crosslinked with an enzymatically cleavable peptide linker are provided and may be used for the oral delivery of a therapeutic. The peptide linker may be cleavable by an enzyme in the small intestine and may allow for the delivery of a therapeutic protein or nucleic acid to the small intestine. Also provided are methods of using the polymers for the treatment of a disease.
    Type: Application
    Filed: February 27, 2018
    Publication date: September 13, 2018
    Inventors: Jennifer M. KNIPE, Laura E. STRONG, Nicholas A. PEPPAS
  • Patent number: 9937256
    Abstract: In some aspects, methacrylate co-polymers crosslinked with an enzymatically cleavable peptide linker are provided and may be used for the oral delivery of a therapeutic. The peptide linker may be cleavable by an enzyme in the small intestine and may allow for the delivery of a therapeutic protein or nucleic acid to the small intestine. Also provided are methods of using the polymers for the treatment of a disease.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: April 10, 2018
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jennifer M. Knipe, Laura E. Strong, Nicholas A. Peppas
  • Publication number: 20170000859
    Abstract: The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such as an antibody, for delivery to pathogenic cells.
    Type: Application
    Filed: July 18, 2016
    Publication date: January 5, 2017
    Inventors: Laura E. Strong, Peter A. Leland, Thomas Burke
  • Publication number: 20160206741
    Abstract: In some aspects, methacrylate co-polymers crosslinked with an enzymatically cleavable peptide linker are provided and may be used for the oral delivery of a therapeutic. The peptide linker may be cleavable by an enzyme in the small intestine and may allow for the delivery of a therapeutic protein or nucleic acid to the small intestine. Also provided are methods of using the polymers for the treatment of a disease.
    Type: Application
    Filed: January 13, 2016
    Publication date: July 21, 2016
    Inventors: Jennifer M. Knipe, Laura E. Strong, Nicholas A. Peppas
  • Patent number: 9393319
    Abstract: The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such as an antibody, for delivery to pathogenic cells.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: July 19, 2016
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Laura E. Strong, Peter A. Leland, Thomas Burke
  • Patent number: 9192656
    Abstract: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: November 24, 2015
    Assignee: QUINTESSENCE BIOSCIENCES, INC.
    Inventors: John A Kink, Laura E. Strong, Mark N. Shahan
  • Publication number: 20150238575
    Abstract: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.
    Type: Application
    Filed: April 27, 2015
    Publication date: August 27, 2015
    Inventors: John A. Kink, Laura E. Strong, Mark N. Shahan
  • Patent number: 8840882
    Abstract: The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in vivo biological activity, stability, and/or reduce host immune response to the protein in vivo) as well as methods of using the conjugates in the therapy, treatment, and/or prevention of disease (e.g., cancer).
    Type: Grant
    Filed: June 25, 2007
    Date of Patent: September 23, 2014
    Assignee: Quintessence Biosciences, Inc.
    Inventors: John A. Kink, Laura E. Strong, Vladimir Trubetskoy, Mark N. Shahan
  • Publication number: 20140212946
    Abstract: The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such as an antibody, for delivery to pathogenic cells.
    Type: Application
    Filed: April 14, 2014
    Publication date: July 31, 2014
    Applicant: Quintessence Biosciences, Inc.
    Inventors: Laura E. Strong, Peter A. Leland, Thomas Burke
  • Patent number: 8697062
    Abstract: The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in vivo biological activity, stability, and/or reduce host immune response to the protein in vivo) as well as methods of using the conjugates in the therapy, treatment, and/or prevention of disease (e.g., cancer).
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: April 15, 2014
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Ronald T. Raines, Thomas J. Rutkoski, John A. Kink, Laura E. Strong
  • Patent number: 8697065
    Abstract: The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such as an antibody, for delivery to pathogenic cells.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: April 15, 2014
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Laura E. Strong, Peter A. Leland, Thomas Burke
  • Publication number: 20140017241
    Abstract: The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such as an antibody, for delivery to pathogenic cells.
    Type: Application
    Filed: June 20, 2013
    Publication date: January 16, 2014
    Applicant: QUINTESSENCE BIOSCIENCES, INC.
    Inventors: Laura E. Strong, Peter A. Leland, Thomas Burke
  • Patent number: 8470315
    Abstract: The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such as an antibody, for delivery to pathogenic cells.
    Type: Grant
    Filed: April 13, 2005
    Date of Patent: June 25, 2013
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Laura E. Strong, Peter A. Leland, Thomas Burke
  • Publication number: 20130078229
    Abstract: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.
    Type: Application
    Filed: October 26, 2012
    Publication date: March 28, 2013
    Inventors: John A Kink, Laura E. Strong, Mark N. Shahan
  • Patent number: 8298801
    Abstract: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: October 30, 2012
    Assignee: Quintessence Biosciences, Inc.
    Inventors: John A. Kink, Laura E. Strong, Mark N. Shahan
  • Publication number: 20090098101
    Abstract: The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in vivo biological activity, stability, and/or reduce host immune response to the protein in vivo) as well as methods of using the conjugates in the therapy, treatment, and/or prevention of disease (e.g., cancer).
    Type: Application
    Filed: October 8, 2008
    Publication date: April 16, 2009
    Applicant: QUINTESSENCE BIOSCIENCES, INC.
    Inventors: Ronald T. Raines, Thomas J. Rutkoski, John A. Kink, Laura E. Strong
  • Publication number: 20030125262
    Abstract: This invention provides multivalent ligands which carry or display at least one recognition element (RE), and preferably a plurality of recognition elements, for binding directly or indirectly to cells or other biological particles or more generally by binding to any biological molecule. The multivalent ligands provided can most generally function for binding or targeting to any biological particle or molecule and particularly to targeting of cells or cell types or viruses, for cell aggregation and generally for macromolecular assembly of biological macromolecules. The multivalent ligands of this invention are generally applicable for creating scaffolds (assemblies) of chemical or biological species, including without limitation, antigens, epitopes, ligand binding groups, ligands for cell receptors (cell surface receptors, transmembrane receptors and cytoplasmic receptors), and various macromolecules (nucleic acids, carbohydrates, saccharides, proteins, peptides, etc.).
    Type: Application
    Filed: March 21, 2001
    Publication date: July 3, 2003
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Laura L. Kiessling , Laura E. Strong , Jason E. Gestwicki
  • Patent number: 6538072
    Abstract: A method of preparing a multivalent array that includes: polymerizing at least one monomer comprising at least one polymerizable group and at least one latent reactive group in the presence of a metal carbene catalyst to form a polymer template comprising at least one latent reactive group; and combining the polymer template with at least one functionalizing reagent comprising at least one reactive group under conditions effective to react the latent reactive group of the polymer template with the reactive group of the functionalizing reagent to form a multivalent array.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: March 25, 2003
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Laura L. Kiessling, Laura E. Strong
  • Publication number: 20020007016
    Abstract: A method of preparing a multivalent array that includes: polymerizing at least one monomer comprising at least one polymerizable group and at least one latent reactive group in the presence of a metal carbene catalyst to form a polymer template comprising at least one latent reactive group; and combining the polymer template with at least one functionalizing reagent comprising at least one reactive group under conditions effective to react the latent reactive group of the polymer template with the reactive group of the functionalizing reagent to form a multivalent array.
    Type: Application
    Filed: June 22, 2001
    Publication date: January 17, 2002
    Inventors: Laura L. Kiessling, Laura E. Strong